These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Overview of hypercalcemia of malignancy. Solimando DA Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S4-7. PubMed ID: 11757205 [TBL] [Abstract][Full Text] [Related]
4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
5. New insights on the pathogenesis of hypercalcemia in primary hyperparathyroidism. Yonemura K; Suzuki H; Fujigaki Y; Hishida A Am J Med Sci; 2000 Nov; 320(5):334-6. PubMed ID: 11093687 [TBL] [Abstract][Full Text] [Related]
6. Significance of parathyroid hormone-related protein as a factor stimulating bone resorption and causing hypercalcemia in myeloma. Tsujimura H; Nagamura F; Iseki T; Kanazawa S; Saisho H Am J Hematol; 1998 Oct; 59(2):168-70. PubMed ID: 9766803 [TBL] [Abstract][Full Text] [Related]
7. Hypercalcemia and cancer: an update. Murray TM; Josse RG; Heersche JN Can Med Assoc J; 1978 Oct; 119(8):915-20. PubMed ID: 367555 [TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and primary hyperparathyroidism. Rodan GA J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793 [TBL] [Abstract][Full Text] [Related]
11. Hypercalcemia induced with the plasma levels of parathyroid hormone-related peptide in multiple myeloma. Shionoiri A; Horiuchi T; Onouchi T; Tsutsumi H; Ohta M; Hosoi T; Ito H; Orimo H Intern Med; 2000 Oct; 39(10):810-3. PubMed ID: 11030205 [TBL] [Abstract][Full Text] [Related]
12. Parathyroid hormone-related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors. Takeuchi Y; Fukumoto S; Nakayama K; Tamura Y; Yanagisawa A; Fujita T J Bone Miner Res; 2002 May; 17(5):753-7. PubMed ID: 12009004 [TBL] [Abstract][Full Text] [Related]
15. 1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion. Endo K; Katsumata K; Hirata M; Masaki T; Kubodera N; Nakamura T; Ikeda K; Ogata E J Bone Miner Res; 2000 Jan; 15(1):175-81. PubMed ID: 10646127 [TBL] [Abstract][Full Text] [Related]
16. [High PTHrP level induced hypercalcemia and acute renal failure in a multiple myeloma patient]. Saito O; Kurosu M; Ando Y; Kusano E; Asano Y Nihon Jinzo Gakkai Shi; 2000 Jan; 42(1):41-6. PubMed ID: 10737013 [TBL] [Abstract][Full Text] [Related]
17. [Hypercalcemia in myeloma]. Abe M Nihon Rinsho; 2007 Dec; 65(12):2245-9. PubMed ID: 18069268 [TBL] [Abstract][Full Text] [Related]
18. Multiple myeloma/hypercalcemia. Oyajobi BO Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S4. PubMed ID: 17634143 [TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population. Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539 [TBL] [Abstract][Full Text] [Related]